Barclays Sticks to Its Hold Rating for DaVita (DVA)
In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on DaVita, with a price target of $194.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Mok CFA is an analyst with an average return of -6.8% and a 48.62% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as Centene, Brookdale Senior Living, and Encompass Health.
Currently, the analyst consensus on DaVita is a Moderate Buy with an average price target of $211.00.
Based on DaVita’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.42 billion and a net profit of $197.53 million. In comparison, last year the company earned a revenue of $3.22 billion and had a net profit of $162.92 million
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DVA in relation to earlier this year. Earlier this month, Kathleen Alyce Waters, the Chief Legal & Pub. Affairs Off of DVA sold 8,950.00 shares for a total of $1,860,168.00.
Read More on DVA:
